No abstract available.
Cleft Lip* ; Congenital Abnormalities*

No abstract available.
Durapatite* ; Forehead*

No abstract available.
Hand* ; Humans

No abstract available.
Cytomegalovirus* ; DNA* ; Humans* ; Polymerase Chain Reaction*

Hand rehabilitation is essential to restore the maximal functional capacity of a patient after the injuries of hand or upper extremity, such as a fracture, tendon tear, crushing, or amputation. To achieve the purpose, hand rehabilitation should begin shortly after the completion of surgery. Especially after the replantation, functional recovery can be achieved by a careful inpatient evaluation providing a proper treatment, detecting problems, and updating treatment programs, and arranging discharge and follow-up cares by a hand rehabilitation team. We report our experience of a successful hand rehabilitation of patient with a replantation surgery after the complete right forearm amputation. A comprehensive approach and systematized treatment programs are important for a hand rehabilitation.
Amputation* ; Follow-Up Studies ; Forearm* ; Hand* ; Humans ; Inpatients ; Rehabilitation* ; Replantation* ; Tendons ; Upper Extremity

Purpose: In the present study, the efficacy and safety of brolucizumab in refractory polypoidal choroidal vasculopathy (PCV) patients treated with aflibercept were investigated. Methods: The medical records of patients with refractory PCV treated with aflibercept were reviewed. All patients had subretinal fluid or intraretinal fluid followed by at least three consecutive injections of aflibercept on a 4–8-week dosing schedule before switching to brolucizumab. Changes in injection intervals, optical coherence tomography (OCT), and OCT angiography parameters including central macular thickness (CMT), subfoveal choroidal thickness (SFCT), polyp height, lesion area, flow density, and polyp regression rate were evaluated before and 6 months after switching to brolucizumab. Results: The study included 32 eyes of 32 patients with PCV who received brolucizumab injections as switch therapy and were followed at 6 months. After switching to brolucizumab, 53% of eyes had dry macula and the injection interval was extended from 5.4 ± 1.7 weeks to 10.8 ± 2.9 weeks. Best-corrected visual acuity remained stable over the 6 months (p = 0.166). CMT and SFCT were reduced at 6 months after switching to brolucizumab (p = 0.042 and p = 0.023, respectively). Polyp regression was complete in 12.5% and partial in 62.5% of eyes. The largest polyp height and lesion size significantly decreased (p = 0.035 and p = 0.010, respectively). However, significant difference was not found regarding flow density after switching to brolucizumab (p = 0.145). Intraocular inflammation-related adverse events were not reported. Conclusions Brolucizumab could provide additional benefits in refractory PCV treated with aflibercept by reducing leakage from polyps, branching vascular networks, and choroid.

Purpose: To evaluate the efficacy of switching to faricimab (VabysmoTM; Roche/Genentech) treatment for patients with neovascular age-related macular degeneration (nAMD) that was resistant to other anti-vascular endothelial growth factor (VEGF) therapies by assessing outcomes after 6 months. Methods: We conducted a retrospective chart review of 102 nAMD patients who were switched to faricimab due to suboptimal responses to prior anti-VEGF treatments. Patients who showed persistent fluid on optical coherence tomography despite prior anti-VEGF injections every 4 to 8 weeks were treated with faricimab. We assessed changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), subfoveal choroidal thickness, maximum pigment epithelial detachment (PED) height, and fluid status at baseline and 1, 3, and 6 months after switching to faricimab. Treatment intervals before and after switching were compared. Results: Six months after switching to faricimab, the mean BCVA improved (0.50 ± 0.12 logMAR to 0.45 ± 0.10 logMAR, p = 0.030), while the mean CST decreased from 353.3 ± 40.5 μm at baseline to 311.4 ± 35.4 μm (p = 0.012). The mean choroidal thickness did not significantly decrease after switching. The mean PED height decreased from 309.1 ± 32.1 μm at baseline to 279.1 ± 30.8 μm at 6 months (p = 0.040). The mean treatment interval extended from 5.7 ± 1.4 to 10.4 ± 1.8 weeks after switching (p = 0.001). Additionally, dry macula was achieved in 43.1% of patients, while 76.5% were classified as good responders, 6.5% as partial responders, and 17% reverted to other anti-VEGF treatments due to non-response. Conclusions Switching nAMD patients to faricimab for 6 months produced substantial improvements in visual acuity and anatomical outcomes, together with extended treatment intervals, reducing the injection burden. Faricimab could be an effective treatment option for nAMD, particularly for patients with inadequate responses to previous therapies.

We have analysed 144 patients with hypertensive putaminal hemorrhage, admitting from January 1992 to December 1993. Surgical treated group with Komai's stereotactic system was 71 patients and medical treated group was 73 patients. The results were as follows: 1) The patients with ventricular rupture were 36 cases(25%). According to the degree of ventricular rupture, the mortality was increased and the good outcome was decreased(P<0.01). 2) The prognosis was evaluated in favorable condition(alert and drowsy) and unfavorable condition(stuporous, semicomatose, comatose). In unfavorable condition, the mortality of surgical patients was lower than that of non-surgical patients(P<0.01). 3) Surgical patients with smaller hematoma(< or = 40ml) showed btter outcome than non-surgical patients:The statistical difference was not significant. But in larger hematoma(>40ml), the outcome in both treated group was similar. 4) According to CT classification, in class II(extending to anterior limb of internal capsule), good outcome of surgical group was better than that of non-surgical group. In class V(extending th thalamus or subthalamus), the mortality in surgical group was lower than that of non-surgical group(P<0.05) .
Classification ; Extremities ; Humans ; Mortality ; Prognosis ; Putaminal Hemorrhage* ; Rupture ; Thalamus

Choroid plexus papillomas are uncommon neoplasms of the central nervous system, accounting for 0.4% to 0.1% of all intracranial tumors. We present a choroid plexus papilloma in the trigone of the lateral ventricle in an 8 months old infant with hydrocephalus. We successfully controlled hydrocephalus and subdural fluid collection after total removal of the mass.
Central Nervous System ; Choroid Plexus* ; Choroid* ; Humans ; Hydrocephalus ; Infant* ; Lateral Ventricles* ; Papilloma, Choroid Plexus* ; Subdural Effusion

No abstract available.
Brain* ; Hydrocephalus*